KBLB (Kraig Biocraft Laboratories) Research & Development: $0.21 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Kraig Biocraft Laboratories Research & Development?

Kraig Biocraft Laboratories KBLB +2.61% Research & Development is $0.21 Mil as of Mar. 2026. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Kraig Biocraft Laboratories's Research & Development for the three months ended in Mar. 2026 was $0.07 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0.21 Mil.

Kraig Biocraft Laboratories  (OTCPK:KBLB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Kraig Biocraft Laboratories Research & Development Related Terms

Kraig Biocraft Laboratories Research & Development Historical Data

* Premium members only.

The historical data trend for Kraig Biocraft Laboratories's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kraig Biocraft Laboratories Research & Development Chart

Kraig Biocraft Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.18 0.24 0.16 0.17

Kraig Biocraft Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.06 0.01 0.07 0.07

Kraig Biocraft Laboratories Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.21 Mil mean?
Kraig Biocraft Laboratories (KBLB) has a Research & Development of $0.21 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Kraig Biocraft Laboratories and its competitors.
Is Kraig Biocraft Laboratories' Research & Development too high?
Kraig Biocraft Laboratories' current Research & Development is $0.21 Mil.
How does Kraig Biocraft Laboratories' Research & Development compare to NTIC and AMTX?
Kraig Biocraft Laboratories' Research & Development of $0.21 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Chemicals company?
A good Research & Development depends on the Chemicals industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Kraig Biocraft Laboratories and its competitors. Kraig Biocraft Laboratories's current Research & Development is $0.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kraig Biocraft Laboratories stock overvalued right now?
Kraig Biocraft Laboratories (KBLB) has a current Research & Development of $0.21 Mil. The current Research & Development is $0.21 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Kraig Biocraft Laboratories (KBLB), the current Research & Development is $0.21 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kraig Biocraft Laboratories Business Description

Address 2723 South State Street, Suite 150, Ann Arbor, MI, USA, 48104
Kraig Biocraft Laboratories Inc is engaged in the development of high-strength fiber using recombinant DNA technology mainly for commercial applications. It uses genetic engineering technologies to develop fibers with greater strength, resiliency, and flexibility for use in its target markets, namely the textile, specialty fiber, and technical textile industries. Its products include Monster Silk, which incorporates the natural elasticity of spider silk to make a silk fiber that is more flexible than conventional silk fibers and textiles; Dragon Silk, which combines the elasticity of Monster Silk with additional high-strength elements of native spider silk; Spydasilk; and Spydra.